预约演示
GC Biopharma and Eubiologics enter deal to produce cholera vaccine
疫苗
The companies will jointly manufacture the cholera vaccine from the first half of 2024. Credit: Andrey_Popov / Shutterstock.com.
South Korean biopharmaceutical firm GC Biopcholeraas signed a memorandum of understanding (MOU) with Eubiologics to jointly manufacture oral cholera vaccine, Euvichol.
Under the deal, both companies will GC Biopharmafor the vaccine supply.EubiologicscholeraEuvichol
Eubiologics will oversee the bulk manufacturing of the vaccine while GC Biopharma will be responsible for conducting the packaging process including the bottling of vials.
Eubiologics will jointly manufacture Euvichol from the first half of GC Biopharmaply to the United Nations International Children’s Emergency Fund (UNICEF).
UNICEF had sought further supply of vEuvicholapart from those of a plastic-tubed Euvichol-Plus to address the recent spread of cholera infection in various areas such as Africa.
Eubiologics and the International Vaccine Institute (IVI) co-developed Euvichol fEuvicholrevention of cholera.
Eubiologics receivedInternational Vaccine Institute (IVI)cation in 2015Euvichol supply of doses to UNIcholerarted in 2016.
As of 2022, a total of 100 million vaccine doses were supplied to the UN agency.
Eubiologics vice-president Kyeong-Ho Min said: “With the more frequent floods and droughts due to climate change and global warming, the world is currently experiencing rapid spread of cholera, leading to a shortage of vaccine supply.
Eubiologicsll be a big boost to the increase of vaccine supply, and it will bring us not only more revenue, but also a way to further contribute to controlling the spread of cholera.”cholera
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。